Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an announcement.
Pharmaron Beijing Co., Ltd. announced that its board of directors will convene on October 28, 2025, to review and approve the company’s third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on providing a variety of pharmaceutical services and products.
Average Trading Volume: 15,769,958
Technical Sentiment Signal: Hold
Current Market Cap: HK$60.6B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.